SCHEMBL563796

SCHEMBL563796

N#CC1CNC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24453092 1.00
SCHEMBL14690544 0.78
SCHEMBL8923843 0.77
SCHEMBL25281135 0.76
SCHEMBL28259478 0.71
SCHEMBL5035574 0.63 MTNR1A (0.41)
SCHEMBL27386789 0.62
SCHEMBL3736282 0.62
SCHEMBL4926015 0.62
SCHEMBL383251 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP claimed
WO-2025017045-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO claimed
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2025017045-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
US-20240246913-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-07-25 US disclosed
EP-4347563-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES Oxford University Innovation Limited (GB) 2024-04-10 EP disclosed
CN-117677606-A 2-carboxy-indole inhibitors of metallo-beta-lactamase 牛津大学创新有限公司 2024-03-08 CN disclosed
WO-2022248887-A1 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2022-12-01 WO disclosed
US-20220162212-A1 PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE HOFFMANN-LA ROCHE INC. (US) 2022-05-26 US disclosed
CN-110804061-B Pyrazole and pyrazine formamide compound containing cyclopropyl segment and application thereof 中国医学科学院医药生物技术研究所 2021-01-05 CN disclosed
US-10781206-B2 Tetrahydropyrazolopyridine compounds for the treatment of infectious diseases HOFFMANN LA-ROCHE INC. (US) 2020-09-22 US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 US disclosed
EP-1452524-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-09-01 EP disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 EP disclosed
US-20040116507-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2004-06-17 US disclosed
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2004-05-06 US disclosed
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2003-06-26 US disclosed
EP-1265862-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2002-12-18 EP disclosed
WO-2001062726-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2001-08-30 WO disclosed